There should be more discussion of patients' suitability for resuscitation between doctors, nurses, patients, and patients' relatives. Suitability for resuscitation should be reviewed on every consultant ward round.
Introduction
Studies of the outcome of cardiopulmonary resuscitation of patients who suffer a cardiac arrest in hospital shows that only 8-7-14 0% are discharged alive.'14 Characteristics of patients before arrest that predict death in hospital include a homebound lifestyle, cancer, hypotension, and renal failure."' With or without specific knowledge of these risk factors for mortality, most doctors and nurses believe that there are some patients for whom resuscitation in the event of cardiopulmonary arrest would be inappropriate for reasons of futility or poor quality of life. This survey showed that prognosis, let alone resuscirvive less than one tation in the event of arrest, was rarely discussed with patients' relatives. In the United States discussion of resuscitation with patients or their relatives, or both, es'perceptions ofpatients' occurs more frequently.8 '0 Indeed, where legislation whether or not attending on resuscitation exists such a discussion is a preconnbers ofpatients dition for writing "Do not resuscitate" orders. We thank the nurses and junior doctors at Fazakerley Hospital for filling in the questionnaires, and Dr F J Nye for his comments on the manuscript.
Hypercalcaemia is a common complication of malignancy. In patients with breast cancer it has traditionally been attributed to skeletal metastases and local osteolysis by tumour derived factors such as interleukin 1, prostaglandins, and tumour necrosis factor.' 2 There is little evidence that these factors cause hypercalcaemia when introduced by injection, and it is assumed that their actions are largely paracrine, involving localised destruction of bone. The biochemical changes seen in some patients with hypercalcaemia and breast cancer are well documented and include increased renal tubular reabsorption of calcium, a decrease in the renal tubular threshold for phosphate reabsorption, and increased excretion of nephrogenous cyclic AMP.34 These abnormalities are consistent with the actions of a tumour derived parathyroid hormone-like factor with effects on both kidney and bone and have led to the hypothesis that the mechanism of hypercalcaemia in breast cancer is mediated humorally by a parathyroid hormone-like peptide. 45 Parathyroid hormone related protein is a hypercalcaemic factor with similar bioactivity to that of parathyroid hormone. Since its isolation in 1987 from cancer cell lines and a carcinoma of the breast,6 strong evidence has accumulated that parathyroid hormone related protein is an important humoral mediator of cancer associated hypercalcaemia in patients with solid tumours, typically squamous carcinoma of lung.78
We have investigated the possibility that parathyroid hormone related protein has a humoral role in
